Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ME - 23andMe Holding Co.
Market Cap 797.97M P/E - EPS this Y 16.70% Ern Qtrly Grth -
Income -631.48M Forward P/E -2.70 EPS next Y 7.30% 50D Avg Chg -7.00%
Sales 199.19M PEG - EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 1.12 EPS next 5Y - 52W High Chg -73.00%
Recommedations 2.00 Quick Ratio 1.29 Shares Outstanding 339.50M 52W Low Chg 10.00%
Insider Own 3.39% ROA -25.77% Shares Float 332.44M Beta 1.19
Inst Own 30.28% ROE -154.21% Shares Shorted/Prior 23.04M/18.98M Price 1.73
Gross Margin 44.79% Profit Margin - Avg. Volume 2,436,843 Target Price 2.00
Oper. Margin -178.05% Earnings Date Aug 8 Volume 2,473,049 Change -4.95%
Healthcare | Diagnostics & Research | United States
About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.

23andMe Holding Co. News
11/21/24 Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential?
11/20/24 23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
11/13/24 23andMe to lay off more than 200 employees amid business struggles
11/13/24 23andMe Holding Co (ME) Q2 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
11/12/24 Q2 2024 23andMe Holding Co. Earnings Call
11/12/24 23andMe is falling apart
11/12/24 23andMe cuts 40% of its workforce
11/12/24 Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
11/12/24 After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
11/12/24 23andMe cuts 40% of its workforce and discontinues therapeutics division
11/12/24 What’s happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA-testing company
11/12/24 23andMe Lays Off 40% of Staff, Shuts Drug Development Business
11/12/24 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
11/11/24 23andMe cuts 40% of its workforce, discontinues all therapy programs
11/11/24 23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
11/07/24 CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
11/07/24 23andMe to Report Q2 FY2025 Financial Results
10/31/24 23andMe turns to CFOs to fill director roles after mass board exit
10/31/24 23andMe appoints three former CFOs as new directors—after the previous board all resigned
10/30/24 23andMe Regains Compliance With Nasdaq Listing Requirements
ME Chatroom

User Image HushNLearn Posted - 12 hours ago

$ME .11c pre_split JUST SAYING

User Image Obliterate_Bashers Posted - 13 hours ago

$ME $1 Target coming very soon 🎯

User Image johnnythehammer Posted - 14 hours ago

$ME $TDOC shares are up 14% on positive earnings… a telehealth company. Hard to believe that Lemonaid health… is about worthless.. 🤔

User Image rik242 Posted - 17 hours ago

$ME & 23

User Image Seho1994 Posted - 18 hours ago

$ME anyway have a good day guys!!! Looking very good to me. Not selling a single stock

User Image Seho1994 Posted - 19 hours ago

$ME Even this guy added another 2k. What stop you guys? Go and buy!!!

User Image Shallowfknvalue Posted - 1 day ago

$ME won't stop accumulating

User Image petrofornow Posted - 1 day ago

$ME Note how price jumped a day prior to news release.. so hedge funds get news a day earlier?

User Image mayafootballer Posted - 1 day ago

$ME Don't even bother with this company anymore. It's over.

User Image Educated_Degenerate Posted - 1 day ago

$ME

User Image Educated_Degenerate Posted - 1 day ago

$ME remember when we hired Beyoncés dad to be a brand ambassador and never heard another word about it? Hahaha

User Image Educated_Degenerate Posted - 1 day ago

$ME the lack financial information on the agreement is frustrating, its why this didn’t go anywhere. That needs to be disclosed so investors have a sense of the going rate for access to the database. We also should be hearing about the extension of the GSKs agreement or lack there of… no one knows.

User Image Educated_Degenerate Posted - 1 day ago

$ME for my boy @Seho1994 +500 shares today. First 100 was bit rash before my coffee haha

User Image Educated_Degenerate Posted - 1 day ago

$ME just tank it already, I got powder.

User Image moneychoice Posted - 1 day ago

$me $MRNA $CISS adding

User Image Seho1994 Posted - 1 day ago

$ME gap filled

User Image Seho1994 Posted - 1 day ago

$ME He’s right but it will give us opportunity to buy more shares

User Image HushNLearn Posted - 1 day ago

$ME That's it? That's tge rally? Keep winning

User Image Coins8 Posted - 1 day ago

$ME msn puts out 7 hit pieces today and 0 big news companies put out info of collab. News manipulation at its finest

User Image egolden08 Posted - 1 day ago

$ME man… this trash has wasted so much of my time and money. I still have a sizable holding (because I averaged down for ages before split) but damn sure wish I didn’t 😂 can we just get bought out so I can accept my losses and forget this ever happened? Thanks. Also FU Anne.

User Image WFC9000 Posted - 1 day ago

$ME Seller is cleaned up this needs some positive news now to get going

User Image The_One_Near_The_Top Posted - 1 day ago

$ME with this Mirador news it makes 23andMe an AI play. The exclusive GSK agreement was great and they made a bunch of money off of it, but now with this partnership and a company that is already utilizing AI and data with Mirador360 I think $ME will take steps in commoditizing their data. This is no longer a dead cat bounce play, but is now something with a bright future. It's clear with the release of the job cuts before earnings (to separate the bad news and the earnings beat) that this company is trying to turn it around and I think that we'll see more announcements in the coming month and a pleasant surprise on the next ER.

User Image Educated_Degenerate Posted - 1 day ago

$ME scaling back in

User Image Coins8 Posted - 1 day ago

$ME get ready for blast off

User Image BullRunner13 Posted - 1 day ago

$ME @MS_Tammy don’t know if you get my feed so sending directly. Good Catalyst. This has been dead for a while.

User Image Seho1994 Posted - 1 day ago

$ME Bull flag formed in hourly The graphs seem to favor the bulls.

User Image Educated_Degenerate Posted - 1 day ago

$ME really need to know how much money this agreement is worth, so I have an updated valuation on the database.

User Image BullRunner13 Posted - 1 day ago

$ME

User Image BullRunner13 Posted - 1 day ago

$ME 😳👀

User Image LintEater Posted - 1 day ago

$ME 23andMe Holding Co. (Nasdaq: ME) and Mirador Therapeutics announced a strategic research collaboration focused on immunology and inflammation-related diseases. Mirador will utilize 23andMe's genetic and phenotypic database, the world's largest crowdsourced platform for genetic research, alongside their proprietary Mirador360™ development engine to advance target validation and precision medicine. The collaboration combines Mirador's extensive repository of immune-mediated disease data, including over two million human molecular profiles, with 23andMe's database, which has previously contributed to multiple drug discovery programs and two clinical stage assets in immuno-oncology. https://www.stocktitan.net/news/ME/23and-me-and-mirador-therapeutics-enter-into-strategic-research-x00lgx5cmjek.html

Analyst Ratings
Citigroup Neutral Apr 16, 24
Citigroup Buy Aug 10, 23
Credit Suisse Outperform May 26, 23
Citigroup Neutral May 26, 23
Berenberg Buy Nov 29, 22
Credit Suisse Outperform Nov 8, 22
Cowen & Co. Outperform Sep 22, 22
Citigroup Neutral Aug 10, 22
Credit Suisse Outperform May 27, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 25 Sell 0.73 38,548 28,140 1,280,349 01/26/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 25 Option 0.42 38,548 16,190 1,318,897 01/26/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 11 Sell 0.72 38,548 27,755 1,280,349 01/12/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 11 Option 0.42 38,548 16,190 1,318,897 01/12/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Nov 02 Sell 0.87 38,548 33,537 1,284,976 11/03/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Nov 02 Option 0.42 38,548 16,190 1,323,524 11/03/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 19 Sell 0.81 38,548 31,224 1,284,976 10/20/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 19 Option 0.42 38,548 16,190 1,323,524 10/20/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 05 Option 0.42 38,548 16,190 1,323,524 10/06/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 05 Sell 0.84 38,548 32,380 1,284,976 10/06/23
Richards William G Head of Therapeutics.. Head of Therapeutics Discovery Sep 05 Sell 1.08 2,538 2,741 211,041 09/06/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Aug 15 Sell 1.32 40,894 53,980 257,140 08/16/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Aug 15 Option 0.42 40,894 17,175 298,034 08/16/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jun 29 Sell 1.72 40,894 70,338 257,140 06/30/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jun 29 Option 0.42 40,894 17,175 298,034 06/30/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Dec 05 Sell 3.25 26,259 85,342 235,829 12/06/22
Hillan Kenneth J. Chief Therapeutics O.. Chief Therapeutics Officer Aug 24 Sell 3.64 8,753 31,861 196,083 08/25/22
Lovell Evan Director Director Mar 10 Buy 4.409 11,467 50,558 11,467 03/11/22